70404-40-9

Upstream product

• 6972-82-3 5,6-diamino-1-methyluracil 
• 140-89-6 potassium ethyl xanthogenate 
• 75-15-0 carbon disulfide 

Downstream Products

• 39140-91-5 1,3-dimethyl-6-phenylthiazolo[2,3-f]purine-2,4(1H,3H)-dione 
• 115847-12-6 1-Methyl-6-phenyl-1H-thiazolo[2,3-f]purine-2,4-dione 
• 115872-78-1 6-(4-Chloro-phenyl)-1-methyl-1H-thiazolo[2,3-f]purine-2,4-dione 
• 115847-14-8 7-Ethyl-1-methyl-6-phenyl-1H-thiazolo[2,3-f]purine-2,4-dione 
• 115847-13-7 1-Methyl-6-(4-nitro-phenyl)-1H-thiazolo[2,3-f]purine-2,4-dione 
• 115847-17-1 2,3-tetramethylene-6-p-chlorobenzoylmethyl-8-methylthiazolo<3,2-f>xanthine 
• 115847-16-0 3-phenyl-6-p-chlorobenzoylmethyl-8-methylthiazolo<3,2-f>xanthine 
• 115847-10-4 3-Methyl-8-[2-(4-nitro-phenyl)-2-oxo-ethylsulfanyl]-3,7-dihydro-purine-2,6-dione 
• 115847-09-1 8-[2-(4-Chloro-phenyl)-2-oxo-ethylsulfanyl]-3-methyl-3,7-dihydro-purine-2,6-dione 
• 115847-08-0 3-Methyl-8-(2-oxo-2-p-tolyl-ethylsulfanyl)-3,7-dihydro-purine-2,6-dione 

Relevant academic research and scientific papers

7,8-substituted-3-methylxanthine compounds as well as preparation method and application thereof

The invention discloses 7,8-substituted-3-methylxanthine compounds as well as a preparation method and an application thereof. The compounds have the structural formula (I) shown in the description, wherein R is aliphatic hydrocarbon, an aromatic ring, an acyl-containing group, a hydroxyl-containing group or a sulfhydryl-containing group; R1 is C1-4 alkyl, halogen substituted C1-4 alkyl, C1-4 alkoxy, halogen, a cyano group, nitryl, acetyl, benzyl, benzyloxy, substituted or unsubstituted C1-4 alkylbenzene, a substituted or unsubstituted amino group, substituted guanidyl, a substituted or unsubstituted phosphate group, a substituted or unsubstituted sulfonic group, a substituted or unsubstituted long-chain fatty alkane or substituted or unsubstituted long-chain fatty amine. The compounds have good inhibition effects on PDE8 (phosphodiesterase type 8), PDE8 is also a potential target of the alzheimer's disease, vascular dementia and diabetes, the compounds take PDE8 as the target, and a drug prepared from the compounds has a better curative effect on alzheimer's disease, vascular dementia and diabetes as well.

Compounds for ceramide-mediated signal transduction

Novel isoquinoloine compounds inhibit inflammatory responses associated with TNF-α and fibroblast proliferation in vivo and in vitro. The compounds of the invention neither appreciably inhibit the activity of cAMP phosphodiesterase nor the hydrolysis of phosphatidic acid, and are neither cytotoxic nor cytostatic. Preferred compounds of the invention are esters. Methods for the use of the novel compounds to inhibit ceramide-mediated intracellular responses to stimuli in vivo (particularly TNF-α) are also described. The methods are expected to be of use in reducing inflammatory responses (for example, after angioplasty), in limiting fibrosis (for example, of the liver in cirrhosis), in inhibiting cell senescence, cell apoptosis and UV induced cutaneous immune suppression.